The cost-effectiveness of human papillomavirus vaccination in the Philippines

Llave, Cecilia; Uy, Maria Esterlita; Lam, Hilton Y.; Aldaba, Josephine G.; Yacapin, Clarence C.; Miranda, Michelle B.; Valverde, Haidee A.; Silva, Wilda T.; Nawaz, Saira; Slavkovsky, Rose; Mooney, Jessica; Vodicka, Elisabeth

doi:10.1016/j.vaccine.2022.05.025

Cited by 14 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, 42.6% of HPV16/18‐associated and 74.4% of HPV16/18/31/33/45/52/58‐associated squamous or glandular intraepithelial neoplasia could theoretically have been prevented by bivalent HPV16/18 and 9‐valent vaccines. Arguments in favor of HPV vaccine cost‐effectiveness and production of herd immunity associated have been presented from several countries 12–14 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Extended human papillomavirus genotype distribution in cervical intraepithelial neoplasia and cancer: Analysis of 40 352 cases from a large academic gynecologic center in China

Tang

Jones

Jiang

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

Our aim was to conduct a large epidemiologic analysis of the distribution of human papilloma virus (HPV) genotypes associated with cervical neoplasias and cancers at a major Chinese gynecologic center. The pathologic database was searched for cervical histopathologic diagnoses with prior HPV genotyping from liquid cervical cytology specimens obtained ≤6 months before biopsy. HPV testing was performed by using the Tellgenplex HPV27 or YanengBio HPV23 genotyping assays. A total of 40 352 cases meeting study criteria were identified. High risk human papillomavirus (hrHPV) was detected in 94.1% of squamous cancers compared to in only 83.3% of cervical adenocarcinomas. The prevalence of multiple HPV infections was highest in cervical intraepithelial neoplasia 1 (CIN1) (33.8%) and decreased with increasing severity of squamous lesions. The distribution of HPV genotypes was similar between CIN1 and histopathologic‐negative cases. HPV16 was one of the three most common hrHPV genotypes before all histopathologic abnormalities, ranging from 72.0% for cervical cancers, 38.7% for CIN2/3/AIS, 13.1% for CIN1, and 9.1% for biopsy‐negative cases. HPV16 and HPV18 accounted for over 87.2% of detected hrHPV genotypes for all glandular intraepithelial neoplastic lesions and cancers, whereas squamous lesions did not show this pattern. 80.3% of cervical cancers were associated with genotypes covered by HPV16/18 vaccines and 89.6% with genotypes covered by 9‐valent vaccination.

show abstract

Section: Discussionmentioning

confidence: 99%

“…effectiveness and production of herd immunity associated have been presented from several countries. [12][13][14] There are several advantages to our study. First, our sample size of 40 352 women including variable cervical neoplasia and cancers is one of the largest studies to date.…”

Section: Distribution Of Hrhpv Genotypes In Endocervical Glandular Le...mentioning

confidence: 99%

Extended human papillomavirus genotype distribution in cervical intraepithelial neoplasia and cancer: Analysis of 40 352 cases from a large academic gynecologic center in China

Tang

Jones

Jiang

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Two quadrivalent HPV vaccines are currently in Phase 3 clinical development. A well-phased multi-age cohort (MAC) campaign and the country’s willingness to accept all HPV vaccines will minimize the risk of shortages and significantly impact the long-term outlook for HPV vaccine supply ( 46 , 81 ). Overall, five vaccines have been approved for marketing and WHO prequalification: 1) Three bivalent (HPV2) vaccines: 1.1) GSK’s Cervarix ® with proprietary AS04 adjuvant, indicated for girls and women, boys and men between 9-45 years of age.…”

Section: Progression Of Hpv Vaccinementioning

confidence: 99%

“…Prices have generally fallen across all sourcing and income groups over the past five years. If there is a reasonable demand for these new products, further price reductions will occur as future new entrants create a more competitive environment ( 46 , 81 ).…”

Section: Progression Of Hpv Vaccinementioning

confidence: 99%

Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective

Ebrahimi,

Yousefi,

Khosravi

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Human papillomavirus (HPV) is a viral infection that, if does not go away, can cause health problems like genital warts and cancer. The national immunization schedules for individuals before sexual debut, significantly decreased HPV-associated mortality and it will be affordable. However, immunization programs remain vulnerable to macroeconomic factors such as inflation, fiscal policy, employment levels, and national income. This review aims to investigate the association between national income in lower-middle-income countries to explore recent advances and potential issues, as well as how to deal with challenges.

show abstract

“…The National Medical Products Administration of China on December 30, 2019 approved the first Chinese vaccine against HPV (Cecolin; Innovax, Beijing Wantai). Cecolin is an Escherichia coli -expressed recombinant bivalent HPV vaccine 12. It is indicated for girls and women 9 through 45 years of age to prevent cervical, vulvar, vaginal, and anal cancers caused by HPV types 16 and 18.…”

Section: Vaccines Against Hpvmentioning

confidence: 99%

Human papillomavirus (HPV) vaccination: a call for action in Italy

Bogani

Ghelardi²,

Sopracordevole

et al. 2023

Int J Gynecol Cancer

View full text Add to dashboard Cite

Human papillomavirus (HPV) is the most common sexually transmitted infection. The implementation of primary prevention aims to reduce the burden of HPV infection and HPV-related disease. However, HPV-related diseases are still a concern, even in high-income countries. Approximately 570 000 new cervical cancer cases are diagnosed in Italy every year. Prophylactic HPV vaccines have been developed to minimize the spread of HPV. Growing evidence supports the administration of HPV vaccines (even just one dose) in reducing the prevalence of HPV infection and HPV-related disease including cancers. HPV vaccines are characterized by a high level of efficacy (>95%) in women who are naïve to HPV; however, they do not increase clearance in patients with ongoing HPV infection. With more than 200 million doses administered to date, HPV vaccines are considered to be safe and effective at preventing HPV-related infections and cancers. In this review we aim to review the current evidence regarding HPV vaccination and to describe trends in HPV vaccination coverage in Italy. In Italy, vaccination against HPV has been included in the National Immunization Plan (NIP) since 2007–2008. Using data abstracted from the Italian Ministry of Health, we analyzed changes in HPV vaccination coverage. We observed that HPV vaccines are underutilized and coverage rates are decreasing. Looking at the target population (females and males aged 11–12 years) in Italy, a decrease in coverage rates was observed. A call for action, improved HPV awareness, and education are the key elements to enhance the widespread adoption of HPV vaccination.

show abstract

The cost-effectiveness of human papillomavirus vaccination in the Philippines

Cited by 14 publications

References 20 publications

Extended human papillomavirus genotype distribution in cervical intraepithelial neoplasia and cancer: Analysis of 40 352 cases from a large academic gynecologic center in China

Extended human papillomavirus genotype distribution in cervical intraepithelial neoplasia and cancer: Analysis of 40 352 cases from a large academic gynecologic center in China

Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective

Human papillomavirus (HPV) vaccination: a call for action in Italy

Contact Info

Product

Resources

About